Establishment and characterization of a cell line (NOMH-1) originating from a human endometrioid adenocarcinoma of the ovary

Journal of Ovarian Research

Yuro Shibayama¹  Mitsuo Kagawa¹  Kaname Shimokawa¹  Hiroshi Mori²  Takayoshi Kanda³  Takashi Yamada¹ 

[1] Department of Pathology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan;Department of Clinical Pathology, Minoh City Hospital, 5-7-1 Kayano, Minoh, Osaka, 562-8562, Japan;Department of Obstetrics and Gynecology, Osaka Minami Medical Center, 2–1 Kidohigashi-machi, Kawachinagano, Osaka, 586-8521, Japan

关键词: Tumor marker;    MTT assay;    Chemosensitivity;    Cell line;    Ovary;    Endometrioid adenocarcinoma;   

Others  :  811137
DOI  :  10.1186/1757-2215-6-8

 received in 2013-01-04, accepted in 2013-01-31,  发布年份 2013

【 摘 要 】

Background

Cell lines are very useful for clinical and basic research. Thus far, only 11 reports have documented the characteristics of ovarian endometrioid adenocarcinoma cell lines in the literature. Due to the scarcity of information, the establishment of an ovarian malignant tumor cell line with distinctive characteristics is particularly important to study this disease. Thus, this study was undertaken to establish and characterize a new human endometrioid adenocarcinoma cell line of the ovary.

Methods

The cell line NOMH-1 was established from an ovarian tumor of a 44-year-old woman. Features of the cell line studied included morphology, chromosome analysis, heterotransplantation, tumor markers, and chemosensitivity.

Results

This cell line has been growing well for 232 months and subcultured more than 50 times. Monolayer cultured cells were polygonal in shape, showing a pavement-like arrangement and a tendency to stack without contact inhibition. They exhibited a human karyotype with a modal chromosomal number in the hypertriploid range. The cells could be transplanted into the subcutis of nude mice and produced tumors resembling the original tumor. NOMH-1 cells expressed both CEA and CA19-9 which were identified immunohistochemically in the original tumor and the heterotransplanted tumor. The cells were sensitive to paclitaxel, an agent commonly used in the treatment of gynecological cancers.

Conclusions

NOMH-1 is the first ovarian endometrioid adenocarcinoma cell line in which CEA and CA19-9 expression have been defined. This newly established cell line should be useful for investigating the characteristics of ovarian endometrioid adenocarcinoma.

【 授权许可】

   
2013 Yamada et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

Figure 11.

【 参考文献 】

• [1]Jiang X, Hitchcock A, Bryan EJ, Watson RH, Englefield P, Thomas EJ, Campbell IG: Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res 1996, 56:3534-3539.
• [2]Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M: Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000, 60:7052-7056.
• [3]Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, Gershenson DM, Lu KH: Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 2004, 94:456-462.
• [4]Papanicolaou GN: A new procedure for staining vaginal smears. Science 1942, 95:438-439.
• [5]Masuda H, Fujihira S, Ueno H, Kagawa M, Katsuoka Y, Mori H: Ultrastructural study on cytotoxic effects of cyclosporine A in spermiogenesis in rats. Med Electron Microsc 2003, 36:183-191.
• [6]Tamura T, Sasaki Y, Nishiwaki Y, Saijo N: Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 1995, 86:1203-1209.
• [7]Taguchi T, Wakui A, Hasegawa K, Niitani H, Furue H, Ohta K, Hattori T: Phase I clinical study of CPT-11. Research group of CPT-11. Gan To Kagaku Ryoho 1990, 17:115-120.
• [8]Yamada T, Ueda M, Otsuki Y, Ueki M, Sugimoto O: Establishment and characterization of a cell line (OMC-3) originating from a human mucinous cystadenocarcinoma of the ovary. Gynecol Oncol 1991, 40:118-128.
• [9]Twentyman PR, Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 1987, 56:279-285.
• [10]Freedman RS, Pihl E, Kusyk C, Gallager HS, Rutledge F: Characterization of an ovarian carcinoma cell line. Cancer 1978, 42:2352-2359.
• [11]Nagai S, Nozawa S, Kurihara S, Mukai M: Cytologic and biologic studies of endometrioid carcinoma of the ovary. Acta Cytol 1983, 27:676-682.
• [12]Uehara S, Soh K, Hoshiai H, Yajima A, Suzuki M, Abe H: Establishment and characterization of human ovarian endometrioid carcinoma cell line. Nihon Sanka Fujinka Gakkai Zasshi 1983, 35:19-26.
• [13]Ishiwata I, Ishiwata C, Soma M, Ishikawa H: Establishment and characterization of two human ovarian endometrioid carcinoma cell lines (with or without squamous cell component). Gynecol Oncol 1986, 25:95-107.
• [14]Fujii T: Establishment and characterization of human ovarian endometrioid carcinoma cell line. Nihon Sanka Fujinka Gakkai Zasshi 1989, 41:161-166.
• [15]van den Berg-Bakker CA, Hagemeijer A, Franken-Postma EM, Smit VT, Kuppen PJ, van Ravenswaay Claasen HH, Cornelisse CJ, Schrier PI: Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics. Int J Cancer 1993, 53:613-620.
• [16]Hirte HW, Kaiser JS, Bacchetti S: Establishment and characterization of four human epithelial ovarian carcinoma cell lines. Cancer 1994, 74:900-906.
• [17]Yuan Y, Kim WH, Han HS, Lee JH, Park HS, Chung JK, Kang SB, Park JG: Establishment and characterization of human ovarian carcinoma cell lines. Gynecol Oncol 1997, 66:378-387.
• [18]Umezu T, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Kikkawa F: Establishment of a new cell line of endometrioid carcinoma of the ovary and its chemosensitivity. Hum Cell 2007, 20:71-76.
• [19]Matsumoto K, Katsumata N, Yamanaka Y, Yonemori K, Kohno T, Shimizu C, Andoh M, Fujiwara Y: The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol 2006, 100:412-416.